Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

In this review, the potential role of the hormone prolactin in skin biology and its implications for treating skin diseases and hair disorders are explored, with a focus on its stress-related impacts and possible immunomodulatory function in the context of COVID-19.

This review highlights that T cells are crucial in regulating hair follicle regeneration and their disruption can lead to alopecia, providing insights into hair disorders related to T cell immune balance and hair follicle regeneration.

This review discusses the potential of cold atmospheric plasma as a selective antitumor therapy for breast cancer but reports no clinical results, emphasizing its promise and the challenges to its use in precision oncology.

This study highlights that ZNF750, a zinc-finger transcription factor, is crucial for epidermal differentiation and barrier formation in skin by activating genes involved in lipid processing and stratum corneum development, and links ZNF750 sequence variations to skin inflammatory diseases like psoriasis.

This review discusses the potential of asiaticoside from Centella asiatica for enhancing wound healing after endoscopic submucosal dissection and highlights delivery strategies to improve its gastrointestinal application; it reports no new clinical results.

In this review, researchers reported that pyroptosis, a type of inflammatory cell death linked to inflammasome activity, is a key factor in the pathogenesis of alopecia areata and may present new therapeutic opportunities, though most treatments are still in early research stages.

In this study, researchers identified three proteins, DEFB1, HGFAC, and CYB5D2, as potential drug targets for alopecia areata, and suggested that the traditional Chinese medicine ingredient cimigenol shows promise in interacting with DEFB1 for potential treatment.

This study reviews the role of skin stem cells in aging and explores how organoids, as opposed to traditional methods, can advance research into aging skin and regenerative therapies.

This study assessed the psychosocial impact and disease burden of alopecia areata among adolescents and adults in Australia, finding substantial impacts on physical, emotional, and quality of life overall, with greater disease burden in patients experiencing more extensive hair loss.

In this study, the researchers identified MJ04, a selective JAK3 inhibitor, as a promising candidate for promoting hair growth, demonstrating efficacy in both animal models and human hair follicle assays with a favorable safety and pharmacokinetic profile.

This study explored the molecular communication between hair matrix cells and dermal papilla cells in cashmere goats, revealing key ligand-receptor pairs and signaling pathways that facilitate intercellular crosstalk and potentially influence hair growth mechanisms.

Topical JAK inhibitors can effectively treat alopecia areata and vitiligo by modulating immune responses.

In this study, conducted at a tertiary care hospital in Chennai, adverse events during blood donation were observed in 0.42% of donors, predominantly affecting first-time male donors, and were mostly vasovagal reactions such as giddiness and sweating.

This study reviewed the role of the JAK/STAT signaling pathway in skin diseases and the potential of JAK inhibitors for treating conditions like psoriasis and atopic dermatitis. Although the findings are promising, the authors concluded it is premature to establish their place in dermatological treatments.

In this study, the bark extract of Albizia saponaria was analyzed for its metabolites and potential anti-alopecia effects, identifying several compounds with predicted affinities for proteins involved in hair loss pathways.

This study found that the JAK1 rs310241 AG genotype is associated with a 4.6-fold increased risk of alopecia areata, whereas JAK2 polymorphisms showed no significant link, suggesting a potential genetic susceptibility factor warranting further research.

JAK inhibitors effectively regrow hair in alopecia areata but hair loss often returns after stopping treatment.

This literature review indicates that tofacitinib, both orally and topically, holds promise as a safe and effective treatment for various dermatological conditions in pediatric patients, though its use requires careful consideration of its benefits and risks.

This review discusses the role of the JAK/STAT pathway in managing alopecia areata and emphasizes the need for further research to determine the ideal JAK inhibitor, as it reports no new clinical results.

This review discusses the role of JAK inhibitors in treating alopecia areata by targeting the JAK/STAT pathway and highlights the promising results but also ongoing challenges such as relapse risk and side effects.

In a mouse study, JAK inhibitors like Jakafi and Xeljanz prevented alopecia areata and aided hair regrowth; similar effects were observed in three patients with the condition.

Deuruxolitinib significantly helps regrow scalp hair in adults with moderate to severe alopecia areata.

CTP-543 effectively promotes hair regrowth in adults with moderate to severe alopecia areata.

This review highlights the potential of ginseng and its metabolites in preventing hair loss, detailing their hair growth-promoting effects observed in numerous preclinical studies, and emphasizing the underlying mechanisms involved.

In this study, selective inhibition of JAK3 signaling effectively prevented and reversed alopecia areata in a mouse model, while JAK2 inhibitors did not restore hair growth.

In this case report, two women with chronic alopecia areata and acute alopecia universalis experienced sustained and near-complete hair regrowth after over a year of treatment with oral ruxolitinib, without significant side effects.

This study suggests that off-label use of baricitinib in children under 12 with alopecia areata may improve hair regrowth, but further research is needed to confirm efficacy and safety.

This review discusses the unclear etiology and potential contributing factors of frontal fibrosing alopecia and reports no new clinical findings.